Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal MelanomaC. Mignard, P. Joly, Aurélie Deschamps Huvier et al.|Journal of Oncology|2018Cited by 82
Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response MechanismBaptiste Louveau, Célèste Lebbé, Matthieu Resche‐Rigon et al.|Clinical Cancer Research|2021Cited by 19
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Alexander C. J. van Akkooi, Michal Kiciński et al.|The Lancet Oncology|2025Cited by 10
Phase I-II open label multicenter study of PD0332991 in <i>BRAF<sup>V600mut</sup></i> metastatic melanoma patients harboring <i>CDKN2A</i> loss and RB1 expression and treated with vemurafenib.Baptiste Louveau, Célèste Lebbé, Matthieu Resche‐Rigon et al.|Journal of Clinical Oncology|2019Cited by 5
Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel databaseJ.‐M. L'Orphelin, Brigitte Dréno, Sara Le Naour et al.|European Journal of Dermatology|2022Cited by 3